# This Peptide > A guide to prescription peptide therapy, organized by goal: weight, sexual health, longevity, recovery and sleep. What the research on each peptide measured, and the licensed telehealth providers that prescribe it. This Peptide is organized by what a reader wants to change: weight, sexual health, longevity, recovery or sleep. For each peptide sold for that goal it explains approved products and conditional compounding pathways, what the human studies measured, and which reviewed telehealth sellers offer treatment. The full guide text, review digests and research sources are at https://thispeptide.org/llms-full.txt. ## At a glance Each line is computed from the site's registries when the file is built, and ends with the page that shows it. - Peptides tracked: 30. https://thispeptide.org/peptides - Approved products or conditional compounding pathways: 11 (Semaglutide, Tirzepatide, Liraglutide, Orforglipron, Sermorelin, NAD+, Glutathione, GHK-Cu, PT-141 (bremelanotide), Tesamorelin and SS-31). Compounding depends on applicable federal and state requirements and prescription conditions. https://thispeptide.org/peptides - Approved branded products with restricted coverage here, no seller linked: 2 (Tesamorelin and SS-31). https://thispeptide.org/peptides/tesamorelin - Research only, no seller, price or dose linked: 19 (MOTS-c, on no compounding list; BPC-157, on no compounding list; Kisspeptin, in FDA's 503A Category 2 for safety risks; CJC-1295, on no compounding list; Ipamorelin, in FDA's 503B Category 2 for safety risks; Epitalon, on no compounding list; DSIP, on no compounding list; TB-500, on no compounding list; Retatrutide, on no compounding list; MK-677, in FDA's 503A Category 2 for safety risks; Thymosin alpha-1, nominated for 503B compounding without adequate support; Oxytocin, status not yet read; KPV, on no compounding list; Melanotan II, on no compounding list; AOD-9604, on no compounding list; Semax, on no compounding list; Selank, on no compounding list; LL-37, on no compounding list; 5-Amino-1MQ, on no compounding list). https://thispeptide.org/compare - Peptide guides: 11. https://thispeptide.org/peptides - Goals covered: 5 (Weight https://thispeptide.org/goals/weight; Sexual health https://thispeptide.org/goals/sexual-health; Longevity https://thispeptide.org/goals/longevity; Recovery https://thispeptide.org/goals/recovery; Sleep https://thispeptide.org/goals/sleep). - Telehealth sellers tracked: 601. https://thispeptide.org/methodology - Sellers reviewed: 460. https://thispeptide.org/reviews - Reviewed sellers that prescribe Semaglutide: 427. https://thispeptide.org/peptides/semaglutide#sellers - Reviewed sellers that prescribe Tirzepatide: 421. https://thispeptide.org/peptides/tirzepatide#sellers - Reviewed sellers that prescribe Liraglutide: 34. https://thispeptide.org/peptides/liraglutide#sellers - Reviewed sellers that prescribe Orforglipron: 37. https://thispeptide.org/peptides/orforglipron#sellers - Reviewed sellers that prescribe Sermorelin: 257. https://thispeptide.org/peptides/sermorelin#sellers - Reviewed sellers that prescribe NAD+: 290. https://thispeptide.org/peptides/nad-plus#sellers - Reviewed sellers that prescribe Glutathione: 168. https://thispeptide.org/peptides/glutathione#sellers - Reviewed sellers that prescribe GHK-Cu: 44. https://thispeptide.org/peptides/ghk-cu#sellers - Reviewed sellers that prescribe PT-141 (bremelanotide): 76. https://thispeptide.org/peptides/pt-141#sellers - Published prescriber boards: 12. https://thispeptide.org/best - Sellers ranked on "Best online prescribers for weight-loss peptides": 434. Scope: Semaglutide, Tirzepatide, Liraglutide and Orforglipron. https://thispeptide.org/best/weight-loss-peptides - Sellers ranked on "Best online prescribers for NAD+ and glutathione": 292. Scope: NAD+ and Glutathione. https://thispeptide.org/best/longevity-peptides - Sellers ranked on "Best sermorelin prescribers for sleep": 257. Scope: Sermorelin. https://thispeptide.org/best/sermorelin-for-sleep - Sellers ranked on "Best online prescribers for recovery peptides": 259. Scope: Sermorelin and GHK-Cu. https://thispeptide.org/best/recovery-peptides - Sellers ranked on "Best PT-141 prescribers online": 76. Scope: PT-141 (bremelanotide). https://thispeptide.org/best/pt-141-prescribers - Sellers ranked on "Best GLP-1 tablets and lozenges, ranked on care": 63. Scope: Semaglutide and Tirzepatide, as oral or sublingual. https://thispeptide.org/best/glp1-without-a-needle - Sellers ranked on "NAD+ injection or nasal spray: the best prescribers": 156. Scope: NAD+, as injection or nasal spray. https://thispeptide.org/best/nad-injection-or-nasal - Sellers ranked on "Best NAD+ nasal spray prescribers": 77. Scope: NAD+, as nasal spray. https://thispeptide.org/best/nad-nasal-spray - Sellers ranked on "Best sermorelin injection prescribers": 138. Scope: Sermorelin, as injection. https://thispeptide.org/best/sermorelin-injection - Sellers ranked on "GLP-1 sellers that name their pharmacy": 155. Scope: Semaglutide and Tirzepatide. https://thispeptide.org/best/glp1-named-pharmacy - Sellers ranked on "Best compounded semaglutide prescribers": 427. Scope: Semaglutide. https://thispeptide.org/best/compounded-semaglutide - Sellers ranked on "Best compounded tirzepatide prescribers": 421. Scope: Tirzepatide. https://thispeptide.org/best/compounded-tirzepatide - Research articles: 165. https://thispeptide.org/research - Tools: 6. https://thispeptide.org/tools - Regulatory statuses last read from their FDA sources: October 2026. https://thispeptide.org/methodology ## Questions readers ask, answered Each answer stands on its own and carries the page it comes from. ### Are peptides legal in the U.S.? Some are. Of the 30 peptides this site tracks, 11 have an FDA-approved product or a potentially eligible compounded preparation: Semaglutide, Tirzepatide, Liraglutide, Orforglipron, Sermorelin, NAD+, Glutathione, GHK-Cu, PT-141 (bremelanotide), Tesamorelin and SS-31. Compounding depends on applicable federal and state requirements and prescription conditions. Tesamorelin and SS-31 count only as brand-name drugs, approved for a use no goal here covers. Coverage here is limited to those approved products, so we link no unverified seller. This coverage limit is not a determination of compounding legality. The other 19 are research only: MOTS-c (on no compounding list), BPC-157 (on no compounding list), Kisspeptin (in FDA's 503A Category 2 for safety risks), CJC-1295 (on no compounding list), Ipamorelin (in FDA's 503B Category 2 for safety risks), Epitalon (on no compounding list), DSIP (on no compounding list), TB-500 (on no compounding list), Retatrutide (on no compounding list), MK-677 (in FDA's 503A Category 2 for safety risks), Thymosin alpha-1 (nominated for 503B compounding without adequate support), Oxytocin (status not yet read), KPV (on no compounding list), Melanotan II (on no compounding list), AOD-9604 (on no compounding list), Semax (on no compounding list), Selank (on no compounding list), LL-37 (on no compounding list) and 5-Amino-1MQ (on no compounding list). Each status is read from an FDA document and dated on the guide or goal page that states it: https://thispeptide.org/peptides. The longer answer: https://thispeptide.org/research/are-peptides-legal ### Is BPC-157 legal to buy? No. BPC-157 has no lawful pharmacy route. On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. FDA source: https://www.fda.gov/media/94155/download (read September 2026). This site links no seller, price or dose for it. Research: https://thispeptide.org/research/bpc-157-human-evidence ### Which peptides are used for weight loss, and which can be prescribed? A licensed U.S. prescriber may provide 4 peptides this site files under weight: Semaglutide (FDA-approved; evidence for weight: large trials), Tirzepatide (FDA-approved; evidence for weight: large trials), Liraglutide (FDA-approved; evidence for weight: large trials) and Orforglipron (FDA-approved; evidence for weight: large trials). Tesamorelin is approved only as a brand-name drug for another use, so no seller is linked for weight. Research only, with no seller, price or dose linked: Retatrutide (on no compounding list), AOD-9604 (on no compounding list) and 5-Amino-1MQ (on no compounding list). 5 boards order the reviewed sellers of these peptides on care: "Best online prescribers for weight-loss peptides" ranks 434 reviewed sellers of Semaglutide, Tirzepatide, Liraglutide and Orforglipron (https://thispeptide.org/best/weight-loss-peptides), "Best GLP-1 tablets and lozenges, ranked on care" ranks 63 reviewed sellers of Semaglutide and Tirzepatide, as oral or sublingual (https://thispeptide.org/best/glp1-without-a-needle), "GLP-1 sellers that name their pharmacy" ranks 155 reviewed sellers of Semaglutide and Tirzepatide (https://thispeptide.org/best/glp1-named-pharmacy), "Best compounded semaglutide prescribers" ranks 427 reviewed sellers of Semaglutide (https://thispeptide.org/best/compounded-semaglutide) and "Best compounded tirzepatide prescribers" ranks 421 reviewed sellers of Tirzepatide (https://thispeptide.org/best/compounded-tirzepatide). Every weight peptide side by side: https://thispeptide.org/goals/weight. The longer answer: https://thispeptide.org/research/peptides-for-weight-loss ### Which peptides can a U.S. telehealth legally prescribe for sleep? A licensed U.S. prescriber may provide 1 peptide this site files under sleep: Sermorelin (compounding conditions apply; evidence for sleep: small studies). Research only, with no seller, price or dose linked: DSIP (on no compounding list) and Selank (on no compounding list). 3 boards order the reviewed sellers of these peptides on care: "Best sermorelin prescribers for sleep" ranks 257 reviewed sellers of Sermorelin (https://thispeptide.org/best/sermorelin-for-sleep), "Best online prescribers for recovery peptides" ranks 259 reviewed sellers of Sermorelin and GHK-Cu (https://thispeptide.org/best/recovery-peptides) and "Best sermorelin injection prescribers" ranks 138 reviewed sellers of Sermorelin, as injection (https://thispeptide.org/best/sermorelin-injection). Every sleep peptide side by side: https://thispeptide.org/goals/sleep. The longer answer: https://thispeptide.org/research/peptides-for-sleep ### Which recovery peptides can be prescribed legally? A licensed U.S. prescriber may provide 2 peptides this site files under recovery: Sermorelin (compounding conditions apply; evidence for recovery: early human data) and GHK-Cu (compounding conditions apply; evidence for recovery: small studies). Research only, with no seller, price or dose linked: BPC-157 (on no compounding list), CJC-1295 (on no compounding list), Ipamorelin (in FDA's 503B Category 2 for safety risks), TB-500 (on no compounding list), MK-677 (in FDA's 503A Category 2 for safety risks), Thymosin alpha-1 (nominated for 503B compounding without adequate support), KPV (on no compounding list) and LL-37 (on no compounding list). 3 boards order the reviewed sellers of these peptides on care: "Best sermorelin prescribers for sleep" ranks 257 reviewed sellers of Sermorelin (https://thispeptide.org/best/sermorelin-for-sleep), "Best online prescribers for recovery peptides" ranks 259 reviewed sellers of Sermorelin and GHK-Cu (https://thispeptide.org/best/recovery-peptides) and "Best sermorelin injection prescribers" ranks 138 reviewed sellers of Sermorelin, as injection (https://thispeptide.org/best/sermorelin-injection). Every recovery peptide side by side: https://thispeptide.org/goals/recovery ### What does the evidence say about sermorelin? The label on each goal describes the size and design of the human studies its guide cites, not whether they were favorable. Sermorelin for sleep, small studies: 2 controlled human studies cited here for sleep, none reporting its size in the abstract. And for recovery, early human data: Only uncontrolled or dosing studies in people are cited here for recovery (2 studies), with no comparison group. Guide, with every study listed: https://thispeptide.org/peptides/sermorelin. Does it work, answered at length: https://thispeptide.org/research/does-sermorelin-work ### Is sermorelin FDA-approved? No. No FDA-approved Sermorelin product is sold today. A compounded preparation may be available only under applicable federal and state requirements and prescription conditions. That is not FDA approval. Component of an FDA-approved drug (GEREF, sermorelin acetate). FDA determined in 2013 that GEREF was not withdrawn from sale for reasons of safety or effectiveness. A compounded preparation is not FDA-approved, and FDA does not review it for safety, effectiveness or quality before it is dispensed. FDA source: https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams (read September 2026). 257 reviewed sellers prescribe it; the guide lists them: https://thispeptide.org/peptides/sermorelin#sellers. Guide: https://thispeptide.org/peptides/sermorelin ### Is tesamorelin FDA-approved? FDA approved a specific branded product; coverage here is limited to it. Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions. FDA source: https://www.fda.gov/media/119229/download (read September 2026). This site links no seller for it. Guide: https://thispeptide.org/peptides/tesamorelin ### Is NAD+ FDA-approved? No. No FDA-approved NAD+ product is sold today. A compounded preparation may be available only under applicable federal and state requirements and prescription conditions. That is not FDA approval. Nicotinamide Adenine Dinucleotide (NAD) is in 503A Category 1 (bulk drug substances under evaluation), covered by FDA's interim compounding policy (list updated May 14, 2026). A compounded preparation is not FDA-approved, and FDA does not review it for safety, effectiveness or quality before it is dispensed. FDA source: https://www.fda.gov/media/94155/download (read September 2026). 290 reviewed sellers prescribe it; the guide lists them: https://thispeptide.org/peptides/nad-plus#sellers. Guide: https://thispeptide.org/peptides/nad-plus ### Is compounded semaglutide FDA-approved? No. Wegovy (semaglutide) injection, NDA 215256, approved for chronic weight management. That approval covers the brand-name product. A compounded semaglutide is not FDA-approved, and FDA does not review it for safety, effectiveness or quality before it is dispensed. The evidence label on its guide (large trials: 1 randomized trial of 1,000 or more people cited here for weight) rests on trials of the approved product, not of compounded versions. FDA source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf (read September 2026). 427 reviewed sellers prescribe it; the guide lists them: https://thispeptide.org/peptides/semaglutide#sellers. Guide: https://thispeptide.org/peptides/semaglutide ### Are peptides safe? It depends on which peptide and where it comes from. 7 peptides this site tracks have an FDA-approved product (Semaglutide, Tirzepatide, Liraglutide, Orforglipron, PT-141 (bremelanotide), Tesamorelin and SS-31), reviewed by FDA for its labeled use. A compounded preparation is not FDA-approved, and FDA does not review it for safety, effectiveness or quality before it is dispensed. FDA lists Kisspeptin and MK-677 in 503A Category 2, the bulk substances that raise significant safety risks. Of the 12 peptide-and-goal pairs on this site's guides, 5 rest on large randomized trials; the others rest on smaller, earlier or no human studies. The longer answer: https://thispeptide.org/research/are-peptides-safe ### How do I choose a peptide prescriber online? Start from the peptide: only 9 peptides can be prescribed and filled through the sellers this site reviews (Semaglutide, Tirzepatide, Liraglutide, Orforglipron, Sermorelin, NAD+, Glutathione, GHK-Cu and PT-141 (bremelanotide)). This site has reviewed 460 of the 601 telehealth sellers it tracks, and its 12 boards order the reviewed sellers of each scope on care: prescriber and intake (25%), labs where the compound calls for them (15%) and pharmacy named (15%), with price 5%. Sellers that pay us a commission are listed first on a board and labeled. Each review says who prescribes, what the intake is, and what the seller says about labs. Boards: https://thispeptide.org/best. How the order is set: https://thispeptide.org/methodology ## Where each peptide stands with the FDA A status is a regulatory fact read from the dated source beside it. It says nothing about whether the peptide works. - Semaglutide: FDA-approved. Wegovy (semaglutide) injection, NDA 215256, approved for chronic weight management. Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf (read September 2026). Guide: https://thispeptide.org/peptides/semaglutide - Tirzepatide: FDA-approved. Zepbound (tirzepatide) injection, NDA 217806, approved for chronic weight management. Source: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217806Orig1s000ltr.pdf (read September 2026). Guide: https://thispeptide.org/peptides/tirzepatide - Liraglutide: FDA-approved. Saxenda (liraglutide) injection, NDA 206321, approved December 23, 2014 for chronic weight management. Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321 (read September 2026). Guide: https://thispeptide.org/peptides/liraglutide - Orforglipron: FDA-approved. Foundayo (orforglipron) tablets, NDA 220934, approved April 1, 2026 for chronic weight management. Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934 (read September 2026). Guide: https://thispeptide.org/peptides/orforglipron - Sermorelin: Compounding conditions apply. Component of an FDA-approved drug (GEREF, sermorelin acetate). FDA determined in 2013 that GEREF was not withdrawn from sale for reasons of safety or effectiveness. Source: https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams (read September 2026). Guide: https://thispeptide.org/peptides/sermorelin - NAD+: Compounding conditions apply. Nicotinamide Adenine Dinucleotide (NAD) is in 503A Category 1 (bulk drug substances under evaluation), covered by FDA's interim compounding policy (list updated May 14, 2026). Source: https://www.fda.gov/media/94155/download (read September 2026). Guide: https://thispeptide.org/peptides/nad-plus - Glutathione: Compounding conditions apply. Glutathione is in 503A Category 1 (bulk drug substances under evaluation), covered by FDA's interim compounding policy (list updated May 14, 2026). Source: https://www.fda.gov/media/94155/download (read September 2026). Guide: https://thispeptide.org/peptides/glutathione - GHK-Cu: Compounding conditions apply. "GHK-Cu (except for injectable routes of administration)" is in 503A Category 1 (list updated May 14, 2026). The injectable route is on no list. Eligible only as topical, nasal spray, oral, sublingual. Source: https://www.fda.gov/media/94155/download (read September 2026). Guide: https://thispeptide.org/peptides/ghk-cu - PT-141 (bremelanotide): FDA-approved. Vyleesi (bremelanotide) injection, NDA 210557, approved June 21, 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Source: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf (read September 2026). Guide: https://thispeptide.org/peptides/pt-141 - Tesamorelin: Approved brand; coverage restricted. Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions. Source: https://www.fda.gov/media/119229/download (read September 2026). Also: FDA notice to compounders (March 23, 2020) https://www.fda.gov/drugs/human-drug-compounding/notice-compounders-changes-affect-compounding-march-23-2020; Drugs@FDA, application 022505 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505; Egrifta WR label (DailyMed) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75. Guide: https://thispeptide.org/peptides/tesamorelin - MOTS-c: Research only. On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source: https://www.fda.gov/media/94155/download (read September 2026). Also: PharmExec (vote counts) https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides; NCPA (outcome) https://ncpa.org/newsroom/qam/2026/07/31/fda-advisory-committee-nominates-six-peptides-pharmacies-compound. - BPC-157: Research only. On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source: https://www.fda.gov/media/94155/download (read September 2026). Also: PharmExec (vote counts) https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides; NCPA (outcome) https://ncpa.org/newsroom/qam/2026/07/31/fda-advisory-committee-nominates-six-peptides-pharmacies-compound. - Kisspeptin: Research only. Kisspeptin-10 is in 503A Category 2 (bulk drug substances that raise significant safety risks), placed there September 29, 2023 and still listed in the May 14, 2026 update. FDA cites a possible risk of immunogenicity and peptide-related impurities, and says it has no, or only limited, safety information for the proposed routes. Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA, safety risks of certain bulk drug substances (Category 2 date and reason) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. - CJC-1295: Research only. On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it. Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - Ipamorelin: Research only. "Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it. Source: https://www.fda.gov/media/94164/download (read September 2026). Also: FDA 503A bulk drug substances categories (updated May 14, 2026) https://www.fda.gov/media/94155/download. - Epitalon: Research only. On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025). Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - DSIP: Research only. On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025). Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - TB-500: Research only. On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source: https://www.fda.gov/media/94155/download (read September 2026). Also: PharmExec (vote counts) https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides; NCPA (outcome) https://ncpa.org/newsroom/qam/2026/07/31/fda-advisory-committee-nominates-six-peptides-pharmacies-compound; FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - Retatrutide: Research only. FDA states that retatrutide and cagrilintide "cannot be used in compounding under federal law", and that they "are not components of FDA-approved drugs and have not been found safe and effective for any condition". It is named on no 503A or 503B list. Source: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (read September 2026). Also: FDA 503A bulk drug substances categories (updated May 14, 2026) https://www.fda.gov/media/94155/download; FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - MK-677: Research only. "Ibutamoren Mesylate" is in 503A Category 2, bulk drug substances that raise significant safety risks (list updated May 14, 2026), and in 503B Category 2 (updated March 21, 2025). Both lists bar it for the same stated reason. Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - Thymosin alpha-1: Research only. "Thymosin alpha-1" is in 503B Category 3, bulk drug substances nominated without adequate support (list updated March 21, 2025). It is named on no 503A list, so no listed compounding route exists for it. Source: https://www.fda.gov/media/94164/download (read September 2026). Also: FDA 503A bulk drug substances categories (updated May 14, 2026) https://www.fda.gov/media/94155/download. - Oxytocin: Status not yet reviewed. Its FDA status has not been read yet, so no seller is linked for it. - KPV: Research only. On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source: https://www.fda.gov/media/94155/download (read September 2026). Also: PharmExec (vote counts) https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides; NCPA (outcome) https://ncpa.org/newsroom/qam/2026/07/31/fda-advisory-committee-nominates-six-peptides-pharmacies-compound; FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - Melanotan II: Research only. On no FDA compounding list. Neither "melanotan" in any spelling nor the related approved substance afamelanotide appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025). Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - AOD-9604: Research only. On no FDA compounding list. AOD-9604 appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - Semax: Research only. On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - Selank: Research only. On no FDA compounding list. Selank appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - SS-31: Approved brand; coverage restricted. Forzinity (elamipretide) received accelerated approval on September 19, 2025, to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. It is a subcutaneous injection; confirmatory evidence of clinical benefit is required. This is not a longevity indication. Only the approved branded product is covered here; this coverage limit does not establish that every compounded preparation is prohibited or permitted. Eligible only as injection. Source: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome (read October 2026). Also: FDA Forzinity trial snapshot and prescribing information https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity; FDA 503A bulk-substance conditions https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act. Guide: https://thispeptide.org/peptides/ss-31 - LL-37: Research only. On no FDA compounding list. Neither LL-37 nor cathelicidin, the family it belongs to, appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025). Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. - 5-Amino-1MQ: Research only. On no FDA compounding list. 5-Amino-1MQ (5-amino-1-methylquinolinium) appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). Source: https://www.fda.gov/media/94155/download (read September 2026). Also: FDA 503B bulk drug substances categories (updated March 21, 2025) https://www.fda.gov/media/94164/download. ## How strong the human evidence is, per goal Each label is set by rule from the studies a guide cites: their design and their size, never whether the result was favorable. A guide that cites no study for a goal gives that goal no label. - SS-31, longevity: no label. No study cited on its guide measured this goal. - Semaglutide, weight: Large trials. 1 randomized trial of 1,000 or more people cited here for weight. - Tirzepatide, weight: Large trials. 1 randomized trial of 1,000 or more people cited here for weight. - Liraglutide, weight: Large trials. 1 randomized trial of 1,000 or more people cited here for weight. - Orforglipron, weight: Large trials. 1 randomized trial of 1,000 or more people cited here for weight. - Tesamorelin, weight: no label. No study cited on its guide measured this goal. - PT-141 (bremelanotide), sexual health: Large trials. 1 randomized trial of 1,000 or more people cited here for sexual health. - Sermorelin, sleep: Small studies. 2 controlled human studies cited here for sleep, none reporting its size in the abstract. - Sermorelin, recovery: Early human data. Only uncontrolled or dosing studies in people are cited here for recovery (2 studies), with no comparison group. - NAD+, longevity: Early human data. Only uncontrolled or dosing studies in people are cited here for longevity (2 studies), with no comparison group. - Glutathione, longevity: Small studies. 1 controlled human study cited here for longevity, the largest with 54 people. - GHK-Cu, recovery: Small studies. 2 controlled human studies cited here for recovery, the largest that reports its size with 13 people. ## Goals - Weight: every peptide filed under weight, with its status, evidence and reviewed sellers (prescribable: Semaglutide, Tirzepatide, Liraglutide, Orforglipron; approved only as a brand drug for another use: Tesamorelin; research only: Retatrutide, AOD-9604, 5-Amino-1MQ). https://thispeptide.org/goals/weight - Sexual health: every peptide filed under sexual health, with its status, evidence and reviewed sellers (prescribable: PT-141 (bremelanotide); research only: Kisspeptin, Oxytocin, Melanotan II). https://thispeptide.org/goals/sexual-health - Longevity: every peptide filed under longevity, with its status, evidence and reviewed sellers (prescribable: NAD+, Glutathione; approved only as a brand drug for another use: SS-31; research only: MOTS-c, Epitalon, Semax). https://thispeptide.org/goals/longevity - Recovery: every peptide filed under recovery, with its status, evidence and reviewed sellers (prescribable: Sermorelin, GHK-Cu; research only: BPC-157, CJC-1295, Ipamorelin, TB-500, MK-677, Thymosin alpha-1, KPV, LL-37). https://thispeptide.org/goals/recovery - Sleep: every peptide filed under sleep, with its status, evidence and reviewed sellers (prescribable: Sermorelin; research only: DSIP, Selank). https://thispeptide.org/goals/sleep ## Peptide guides (11) One guide per peptide a prescriber may provide: what it is, how it acts, what the cited human studies measured and what they did not. - Every guide on one page: https://thispeptide.org/peptides - SS-31 (approved brand; coverage restricted; evidence for longevity: no label): SS-31 is elamipretide, the medicine approved as Forzinity for Barth syndrome. Human trials answer different questions, and none of the evidence here establishes an anti-aging treatment. https://thispeptide.org/peptides/ss-31 - Semaglutide (FDA-approved; evidence for weight: large trials): A once-weekly GLP-1 injection with some of the largest trials of any drug on this site. The trials studied the approved product; most telehealth sellers dispense a compounded version. https://thispeptide.org/peptides/semaglutide - Tirzepatide (FDA-approved; evidence for weight: large trials): A once-weekly injection that acts on two gut-hormone receptors. Its obesity trial is among the largest on this site, and a withdrawal trial measured what happens when it stops. https://thispeptide.org/peptides/tirzepatide - Liraglutide (FDA-approved; evidence for weight: large trials): A once-daily GLP-1 injection, approved for weight management as Saxenda in 2014. Two 56-week trials measured how much weight it took off, and how much of a diet's loss it helped keep off. https://thispeptide.org/peptides/liraglutide - Orforglipron (FDA-approved; evidence for weight: large trials): A once-daily GLP-1 tablet, and a small molecule rather than a peptide. Its 72-week phase 3 trial in 3,127 adults measured weight loss against placebo, not against the injected drugs. https://thispeptide.org/peptides/orforglipron - Tesamorelin (approved brand; coverage restricted; evidence for weight: no label): A daily injection approved for one use: excess belly fat in adults with HIV-associated lipodystrophy. Its trials measured fat around the organs, and its label says it is not a weight-loss drug. https://thispeptide.org/peptides/tesamorelin - PT-141 (bremelanotide) (FDA-approved; evidence for sexual health: large trials): The one peptide on this site approved for sexual desire. Two phase 3 trials support it for premenopausal women with low desire; the benefit they measured was modest and nausea was common. https://thispeptide.org/peptides/pt-141 - Sermorelin (compounding conditions apply; evidence for sleep: small studies; recovery: early human data): A short copy of the hormone that tells the pituitary to release growth hormone. Small 1990s studies show it raises growth hormone; none tested it against placebo for aging, body composition or sleep. https://thispeptide.org/peptides/sermorelin - NAD+ (compounding conditions apply; evidence for longevity: early human data): A coenzyme every cell uses to make energy, now sold as injections and nasal sprays. It may be compounded under qualifying conditions. This guide covers two small human IV studies and preclinical nasal research. https://thispeptide.org/peptides/nad-plus - Glutathione (compounding conditions apply; evidence for longevity: small studies): The body's own antioxidant, sold as injections, sprays and tablets. Taken by mouth it raises the body's stores while you take it; in the trials that tested a disease outcome it did not beat placebo. https://thispeptide.org/peptides/glutathione - GHK-Cu (compounding conditions apply; evidence for recovery: small studies): A copper-carrying peptide sold for skin and healing. FDA's interim compounding list covers only its non-injectable forms, and the human trials are about wounds, with mixed results. https://thispeptide.org/peptides/ghk-cu ## Prescriber boards (12) A board lists the reviewed sellers inside one scope. The rubric reads each seller's review: prescriber and intake 25%, labs where the compound calls for them 15%, pharmacy named 15%, dosing guidance 10%, follow-up 10%, stays within legal scope 10%, state coverage 5%, price against the market 5%, price as the dose rises 5%. A mark the review does not record is left out and the other weights are rescaled; it never counts as a zero. - Every board, and why others are not yet published: https://thispeptide.org/best - Best online prescribers for weight-loss peptides: 434 reviewed sellers of Semaglutide, Tirzepatide, Liraglutide and Orforglipron. Ordered on the care around a GLP-1: a named clinician, a named pharmacy and follow-up through the dose steps, with the price as a minor input. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/weight-loss-peptides - Best online prescribers for NAD+ and glutathione: 292 reviewed sellers of NAD+ and Glutathione. Compare who assesses treatment, which pharmacy dispenses it and what the provider publishes about monitoring. A wellness product listing does not establish a longevity benefit. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/longevity-peptides - Best sermorelin prescribers for sleep: 257 reviewed sellers of Sermorelin. Compare prescriber access, monitoring and pharmacy disclosure. Laboratory information helps explain care, but does not establish that sermorelin improves sleep. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/sermorelin-for-sleep - Best online prescribers for recovery peptides: 259 reviewed sellers of Sermorelin and GHK-Cu. Compare who evaluates treatment, how follow-up works and which preparation is supplied. A recovery claim does not establish an injury-healing benefit. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/recovery-peptides - Best PT-141 prescribers online: 76 reviewed sellers of PT-141 (bremelanotide). Ordered on the prescriber and the pharmacy, for a peptide approved only as one brand for one use. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/pt-141-prescribers - Best GLP-1 tablets and lozenges, ranked on care: 63 reviewed sellers of Semaglutide and Tirzepatide, as oral or sublingual. Only sellers that price a GLP-1 you do not inject, each ranked on that product rather than on its injection, which is priced and studied differently. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/glp1-without-a-needle - NAD+ injection or nasal spray: the best prescribers: 156 reviewed sellers of NAD+, as injection or nasal spray. Only sellers that publish a price for NAD+ in a stated form, so each can be read on the form you would actually take. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/nad-injection-or-nasal - Best NAD+ nasal spray prescribers: 77 reviewed sellers of NAD+, as nasal spray. Only the nasal spray, priced as a spray. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/nad-nasal-spray - Best sermorelin injection prescribers: 138 reviewed sellers of Sermorelin, as injection. Only sermorelin by injection, priced as an injection. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/sermorelin-injection - GLP-1 sellers that name their pharmacy: 155 reviewed sellers of Semaglutide and Tirzepatide. Only sellers that name their compounding pharmacy. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/glp1-named-pharmacy - Best compounded semaglutide prescribers: 427 reviewed sellers of Semaglutide. Semaglutide alone. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/compounded-semaglutide - Best compounded tirzepatide prescribers: 421 reviewed sellers of Tirzepatide. Tirzepatide alone. Sellers that pay us are listed first and labeled; the rest follow the rubric. https://thispeptide.org/best/compounded-tirzepatide ## Side by side - Goal line-ups: every peptide under each goal in one table, with its FDA status, evidence label and how many tracked sellers publish a price. https://thispeptide.org/compare - Semaglutide Sodium vs Base: Why the Ingredient Matters: FDA distinguishes semaglutide base from sodium and acetate salts. Here is what a label can establish, what a purity claim cannot, and what to ask the pharmacy. https://thispeptide.org/research/semaglutide-sodium-vs-base - NAC vs Glutathione: Which One Raises Glutathione in People?: NAC hands cells the building block they run short of; glutathione capsules try to deliver the finished molecule. Here is what the trials measured for each, including the one small head-to-head. https://thispeptide.org/research/nac-vs-glutathione - Liraglutide vs Semaglutide: Daily and Weekly GLP-1 Shots Compared: Both copy the same gut hormone, but one lasts about 13 hours and the other about a week. How that shapes their dosing, and what happened when a 68-week trial tested them head to head. https://thispeptide.org/research/liraglutide-vs-semaglutide - NMN vs NAD: How the Precursor and the Molecule Itself Compare in Human Studies: NMN is a building block the body turns into NAD+. It is sold as an oral supplement and has randomized trials; NAD+ itself is compounded for injection or IV and has far fewer. No trial has compared them directly. https://thispeptide.org/research/nmn-vs-nad - Sermorelin vs HGH: A Signal to the Pituitary or the Hormone Itself: Sermorelin asks the pituitary to release growth hormone; HGH is the hormone. No trial has compared them head to head in adults, and their legal and evidence records differ sharply. https://thispeptide.org/research/sermorelin-vs-hgh - GHK-Cu: Copper Peptide Evidence, Topical Versus Injected: Two small skin trials, no injection trials, and an FDA list that allows the peptide by every route except the needle. What each route has behind it. https://thispeptide.org/research/ghk-cu-topical-vs-injected - Sermorelin vs Ipamorelin: Two Very Different Evidence Records: No head-to-head trial turns up in PubMed. One was an approved drug with a year-long pediatric trial; the other has a dosing study and a trial that missed its goal. https://thispeptide.org/research/sermorelin-vs-ipamorelin - Tesamorelin vs Sermorelin: Two GHRH Analogs With Very Different Evidence: Both copy the hormone that tells the pituitary to release growth hormone. One has FDA-approved trials in more than 800 people; the other has two small studies in older men. https://thispeptide.org/research/tesamorelin-vs-sermorelin - Tirzepatide vs Semaglutide: What the Head-to-Head Trials Found: Two randomized trials compared the drugs directly. Tirzepatide produced more weight loss in both, and both trials were open-label and paid for by its maker. https://thispeptide.org/research/tirzepatide-vs-semaglutide ## Tools (6) - All tools: https://thispeptide.org/tools - Peptide goal finder: Pick what you want to change. It lists the peptides filed under that goal, whether a licensed seller may prescribe each one, and how strong the human evidence is. https://thispeptide.org/tools/goal-finder - Reconstitution and dose calculator: Enter the mg in your vial, the water you add and your prescribed dose. It returns the concentration, the U-100 syringe reading and the doses per vial for semaglutide, sermorelin and the other peptides sold as injections. https://thispeptide.org/tools/reconstitution-calculator - mg, mL and syringe unit converter: Enter how concentrated your liquid is and any amount in mg, mcg, mL or insulin-syringe units. It returns the other three, the mark a syringe can actually be drawn to, the doses a vial holds, and the assumption behind every figure. https://thispeptide.org/tools/dose-unit-converter - Peptide comparator: Set two or three peptides next to each other: FDA status, the goals each is looked up for, the evidence behind each goal, the forms sellers price and the largest human study. https://thispeptide.org/tools/peptide-comparator - Sellers in your state: Pick your state and, if you like, a peptide. It lists the reviewed sellers whose own published list names your state, with their prices for that peptide, and puts the sellers that publish no list in a group of their own. https://thispeptide.org/tools/sellers-by-state - Missed-dose checker: Pick the medicine and say how long it has been. It quotes that product's FDA label on a missed dose, shows which part of the rule your timing falls in, and links the label on DailyMed. https://thispeptide.org/tools/missed-dose-checker ## Research library (165), by goal - The whole library: https://thispeptide.org/research ### Weight (66) - Tirzepatide Headache: What the Labels and Trial Results Recorded: Headache is not on either tirzepatide label's list of common side effects. https://thispeptide.org/research/tirzepatide-headache - Does Tirzepatide Make You Tired? What the Trials and Labels Show: In the Zepbound weight trials, 5% to 7% reported fatigue against 3% on placebo, more often early on. https://thispeptide.org/research/does-tirzepatide-make-you-tired - Does Glutathione Help With Weight Loss? What the Human Studies Measured: No trial has tested glutathione for weight loss. https://thispeptide.org/research/does-glutathione-help-with-weight-loss - Ozempic Diarrhea: How Common It Is, How Long It Lasts and When to Call: Diarrhea affected about 9% of people on Ozempic in the diabetes trials and 30% at the higher Wegovy dose. https://thispeptide.org/research/ozempic-diarrhea - Ozempic Stomach Paralysis: What Trials and Case Reports Show: Ozempic slows stomach emptying, and its label says it is not recommended for severe gastroparesis. https://thispeptide.org/research/ozempic-stomach-paralysis - Can Ozempic Cause Low Blood Sugar? Hypoglycemia Risk, Symptoms and Who Runs Low: Ozempic alone rarely drops blood sugar too far, because it raises insulin only when sugar is high. https://thispeptide.org/research/can-ozempic-cause-low-blood-sugar - Can Ozempic Cause Kidney Problems? Kidney Injury, Dehydration and the FLOW Trial: The Ozempic label warns of acute kidney injury, mostly after dehydration from stomach side effects. https://thispeptide.org/research/can-ozempic-cause-kidney-problems - Ozempic Pancreatitis: The Label Warning, the Symptoms and What Trials Show: The Ozempic label warns that acute pancreatitis, including fatal cases, has been seen with GLP-1 drugs. https://thispeptide.org/research/ozempic-pancreatitis - Ozempic and Depression: What FDA's Review of Suicidal Thoughts Found: FDA's January 2026 review found no increased risk of suicidal thoughts or behavior with GLP-1 drugs, and no increased risk of depression in 91 trials. https://thispeptide.org/research/ozempic-depression - Ozempic Blindness: NAION, Vision Loss and What Regulators Concluded: The vision-loss concern is NAION, a sudden loss of blood flow to the optic nerve. https://thispeptide.org/research/ozempic-blindness - Ozempic Thyroid Cancer Risk: The Boxed Warning, Rodent Data and Human Studies: Ozempic's boxed warning comes from thyroid C-cell tumors in mice and rats. https://thispeptide.org/research/ozempic-thyroid-cancer - Intermittent Fasting and GLP-1 Drugs: What the Guidance and Fasting Studies Show: No trial has tested intermittent fasting added to a GLP-1 drug for weight loss. https://thispeptide.org/research/intermittent-fasting-and-glp-1 - Does Ozempic Cause Dehydration? The Kidney Warning, Trial Rates and Fluid Guidance: Ozempic does not dry you out by itself. Its label ties dehydration to fluid lost through nausea, vomiting and diarrhea, which in rare cases injured the kidneys. Here is how often, when, and what guidance says about fluids. https://thispeptide.org/research/does-ozempic-cause-dehydration - Ozempic and Coffee: The Tablet's 30-Minute Rule and What the Pen Label Says: The Ozempic injection label never mentions coffee. https://thispeptide.org/research/ozempic-and-coffee - Ozempic Feet: Foot Drop, Numbness and Heel Pain in the GLP-1 Evidence: Neither label mentions the feet. The documented problem is foot drop from a pinched nerve at the knee after fast weight loss, seen in case reports and a case-control study, while the fat pad under the foot has never been measured on these drugs. https://thispeptide.org/research/ozempic-feet - Ozempic Breasts: What Studies Show About Breast Size, Shape and Density: No GLP-1 trial has measured the breasts. https://thispeptide.org/research/ozempic-breasts - Ozempic Butt: What the Trials Measured Below the Waist, and What They Never Did: No semaglutide or tirzepatide trial has measured the buttocks. https://thispeptide.org/research/ozempic-butt - GLP-1 Medications for Seniors: What the Labels Say After 65: No GLP-1 label's geriatric section sets a separate dose after 65, and each reports no overall difference in effectiveness by age. https://thispeptide.org/research/glp-1-medications-for-seniors - Wegovy for Teens: What the Label and the STEP TEENS Trial Show: Wegovy injection is labeled for weight reduction from age 12. https://thispeptide.org/research/wegovy-for-teens - Ozempic While Breastfeeding: What the Labels and Milk Studies Show: Injected semaglutide was undetectable in the milk of eight nursing mothers, and a single tirzepatide dose left 164 of 171 samples below detection. https://thispeptide.org/research/ozempic-while-breastfeeding - Ozempic and Gallbladder Problems: What the Labels and Trials Show: Gallstones were reported by 1.6% on Wegovy against 0.7% on placebo, and the Ozempic, Wegovy, Mounjaro and Zepbound labels all warn about gallbladder disease. https://thispeptide.org/research/ozempic-and-gallbladder - Ozempic and Anesthesia: What Guidance Says About Surgery: GLP-1 labels warn of rare aspiration under anesthesia and say the data cannot yet show whether pausing helps. https://thispeptide.org/research/ozempic-and-anesthesia - Sulfur Burps on Ozempic and Zepbound: What the Labels Count: Drug labels call it eructation. Wegovy 2.4 mg reported it in 7% of adults against under 1% on placebo, and Zepbound in 4% to 5% against 1%. No label or study records the sulfur smell itself. https://thispeptide.org/research/sulfur-burps-ozempic - Why Is B12 Added to Semaglutide? Glycine, B6 and Niacinamide Too: Compounded semaglutide and tirzepatide are sold with B12, glycine, niacinamide or B6. https://thispeptide.org/research/why-is-b12-added-to-semaglutide - Does Sublingual Semaglutide Work? What Studies Show: Compounded semaglutide is sold to dissolve under the tongue, while the approved tablet must be swallowed whole. https://thispeptide.org/research/does-sublingual-semaglutide-work - Cagrilintide: What the Amylin Trials Actually Measured: An amylin receptor agonist, tested mostly as half of CagriSema. https://thispeptide.org/research/cagrilintide - AOD-9604: the rat study behind the fat-loss claim: AOD-9604 is the fat-burning fragment of growth hormone. https://thispeptide.org/research/aod-9604 - Tirzepatide and Birth Control: What the Label Requires: Switch to a non-oral method or add a barrier method for four weeks after starting and four weeks after every dose increase. https://thispeptide.org/research/tirzepatide-and-birth-control - What to Eat on Tirzepatide: What the Trials Prescribed: The label asks only for a reduced-calorie diet and more activity. https://thispeptide.org/research/what-to-eat-on-tirzepatide - Semaglutide for PCOS: What the Trials Have Actually Measured: Four randomized trials, 176 women and only 23 of them on semaglutide. https://thispeptide.org/research/semaglutide-for-pcos - Tirzepatide Plateau: When Weight Loss Slows in the Trials: Mean loss reached 20.9% on 15 mg at week 72 and had barely moved by week 176. https://thispeptide.org/research/tirzepatide-plateau - What Happens When You Stop Taking Tirzepatide: The Trial Data: In SURMOUNT-4, people switched to placebo after a 20.9% loss regained 14.0% of body weight over 52 weeks, while those who continued lost a further 5.5%. https://thispeptide.org/research/what-happens-when-you-stop-taking-tirzepatide - GLP-1 Muscle Loss: How Much of the Weight Lost Is Lean Mass, and What Limits It: GLP-1 drugs remove more fat than lean tissue, but about a quarter of the weight lost is lean mass in several pooled analyses, similar to diet alone. https://thispeptide.org/research/glp-1-muscle-loss - How Long Does It Take for Tirzepatide to Work? Appetite, Weight and the Week-12 Mark: Appetite changes within weeks: a 6-week trial measured about 525 fewer calories at a test lunch by week 3. https://thispeptide.org/research/how-long-does-it-take-for-tirzepatide-to-work - NAD for Weight Loss: What Human Trials of NAD+ and Its Precursors Found: Searches found no trial that gave NAD+ itself by injection to test weight loss. https://thispeptide.org/research/nad-for-weight-loss - Ozempic and Alcohol: Can You Drink on Semaglutide, and Does It Curb Drinking?: Neither the Ozempic nor the Wegovy label has a drinking warning, but its pancreatitis, low blood sugar and dehydration warnings are where alcohol matters. https://thispeptide.org/research/ozempic-and-alcohol - Ozempic Face: What Studies Measured and Whether It Is the Drug or the Weight Loss: "Ozempic face" is not a listed side effect. https://thispeptide.org/research/ozempic-face - Ozempic Nausea: How Common It Is, When It Fades and What Helps: Nausea is the most reported side effect of semaglutide: 44% on Wegovy 2.4 mg against 16% on placebo, and up to 20.3% on Ozempic for diabetes. https://thispeptide.org/research/ozempic-nausea - Semaglutide Headache: What the Trials Recorded and What Headache Studies Found: In the Wegovy 2.4 mg weight trials, 14% reported headache against 10% on placebo, and the gap was smaller at 7.2 mg. https://thispeptide.org/research/semaglutide-headache - Tirzepatide Diarrhea: Trial Rates, Timing and the Steps Guidance Lists: In the Zepbound weight trials, 19% to 23% reported diarrhea against 8% on placebo. https://thispeptide.org/research/tirzepatide-diarrhea - How Much Weight Can You Lose on Semaglutide? What the STEP Trials Measured: Adults without diabetes lost about 15% of body weight over 68 weeks on 2.4 mg, and half lost 15% or more. https://thispeptide.org/research/how-much-weight-can-you-lose-on-semaglutide - Liraglutide Dosage: The Saxenda and Victoza Dose Steps, and the 16-Week Rule: The weight label climbs from 0.6 mg to 3 mg daily over five weeks, and the diabetes label stops at 1.8 mg. https://thispeptide.org/research/liraglutide-dosage - Ozempic and Pregnancy: What the Label Says and What Exposed Pregnancies Showed: The Ozempic label says to stop at least 2 months before a planned pregnancy, and animal studies found fetal harm. https://thispeptide.org/research/ozempic-and-pregnancy - Semaglutide Constipation: How Common It Is, How Long It Lasts, and What Guidance Suggests: About 24% of people on Wegovy 2.4 mg reported constipation in its weight trials, against 11% on placebo. https://thispeptide.org/research/semaglutide-constipation - What to Eat on Semaglutide: The 2025 Nutrition Advisory, Protein and Side Effects: No diet has been tested head to head on semaglutide. https://thispeptide.org/research/what-to-eat-on-semaglutide - How Long Does It Take for Semaglutide to Work? What Happens Week by Week: Hunger usually changes before weight does. https://thispeptide.org/research/how-long-does-it-take-for-semaglutide-to-work - How Much Weight Can You Lose on Tirzepatide? What the SURMOUNT Trials Measured: Adults without diabetes lost 15% to 21% of their weight over 72 weeks, depending on dose, and about half on the top doses lost a fifth or more. https://thispeptide.org/research/how-much-weight-can-you-lose-on-tirzepatide - Semaglutide Dosage: The Wegovy and Ozempic Dose Steps, and the New 7.2 mg Ceiling: Wegovy climbs from 0.25 mg to 2.4 mg over 16 weeks, and its label now allows 7.2 mg. https://thispeptide.org/research/semaglutide-dosage - Semaglutide Hair Loss: How Often It Happens, in Whom, and Why: Hair loss is on the Wegovy label: 3.3% on 2.4 mg against 1% on placebo, mostly in women, and more on the 7.2 mg dose. https://thispeptide.org/research/semaglutide-hair-loss - Tirzepatide and Alcohol: What the Label Says and What Studies of Drinking Found: The Zepbound label lists no alcohol interaction, but two of its warnings, pancreatitis and gallbladder disease, sit close to drinking. https://thispeptide.org/research/tirzepatide-and-alcohol - Liraglutide Side Effects: What Saxenda's Trials Recorded, Week by Week: Nausea affected 39% of adults on Saxenda against 14% on placebo, mostly in the first six weeks. https://thispeptide.org/research/liraglutide-side-effects - Semaglutide Side Effects: What the Wegovy Trials and Label Recorded: Stomach and bowel effects affected 73% of adults on Wegovy 2.4 mg in its weight trials, against 47% on placebo. https://thispeptide.org/research/semaglutide-side-effects - Sermorelin for Weight Loss: What GHRH Trials Measured, and What They Never Tested: No trial has tested sermorelin as a weight-loss drug. https://thispeptide.org/research/sermorelin-for-weight-loss - Foundayo: Orforglipron's Doses, Trial Results and Side Effects: Foundayo is orforglipron, a daily GLP-1 tablet approved in April 2026. https://thispeptide.org/research/foundayo - Liraglutide vs Semaglutide: Daily and Weekly GLP-1 Shots Compared: Both copy the same gut hormone, but one lasts about 13 hours and the other about a week. https://thispeptide.org/research/liraglutide-vs-semaglutide - Microdosing Semaglutide: What Low-Dose Trials Show, and What No Trial Tested: No trial has tested microdosing semaglutide. https://thispeptide.org/research/microdosing-semaglutide - Tirzepatide Side Effects: What the Zepbound Label and Trials Recorded: Stomach and bowel effects affected more than half of people in the Zepbound weight trials. https://thispeptide.org/research/tirzepatide-side-effects - Peptides for Weight Loss: What the Evidence Shows Beyond Semaglutide and Tirzepatide: The peptides with real weight-loss evidence are close relatives of the GLP-1 drugs. https://thispeptide.org/research/peptides-for-weight-loss - Retatrutide: What the Triple-Agonist Trials Show So Far: A weekly injection aimed at three receptors, with 24.2% average weight loss at the top phase 2 dose. https://thispeptide.org/research/retatrutide - Tesamorelin: What the Egrifta Trials Showed, and What They Did Not: Tesamorelin cut deep belly fat in people with HIV, and the effect faded when they stopped. https://thispeptide.org/research/tesamorelin - Tesamorelin Dosage: What the Egrifta Label States and What the Trials Gave: The Egrifta labels state 1.28 mg or 1.4 mg once daily, and every trial used 2 mg. https://thispeptide.org/research/tesamorelin-dosage - Tesamorelin Side Effects: What the Egrifta Trials and Label Recorded: Injection-site reactions, joint and muscle pain, swelling, higher blood sugar and IGF-1 above the normal range. https://thispeptide.org/research/tesamorelin-side-effects - Tirzepatide Dosage: The Label's Dose Steps and What the SURMOUNT Trials Used: The label starts at 2.5 mg a week and climbs in 2.5 mg steps to a 15 mg ceiling. https://thispeptide.org/research/tirzepatide-dosage - Tirzepatide vs Semaglutide: What the Head-to-Head Trials Found: Two randomized trials compared the drugs directly. https://thispeptide.org/research/tirzepatide-vs-semaglutide - Wegovy Pill: What the Oral Semaglutide Weight Trials Showed: The daily Wegovy pill cut weight 13.6% against 2.2% on placebo over 64 weeks. https://thispeptide.org/research/wegovy-pill - What Happens When You Stop Taking Semaglutide: The Trial Extension Data: Three trials stopped the drug on purpose. https://thispeptide.org/research/what-happens-when-you-stop-taking-semaglutide ### Sexual health (13) - Vyleesi Drug Interactions: Birth Control, Naltrexone and Alcohol: Vyleesi is injected but can slow how pills are absorbed. https://thispeptide.org/research/vyleesi-drug-interactions - Melanotan 2: what the research shows, and what went wrong: Melanotan II is not inert: a controlled study produced erections in 12 of 19 injections. https://thispeptide.org/research/melanotan-2 - Ozempic and Sex Drive: What the Evidence Shows: The label says nothing about it. Meta-analyses in men find testosterone and erectile scores improving, one records study found erectile dysfunction diagnosed 26% more often until the authors calibrated it away, and the evidence in women is case reports. https://thispeptide.org/research/ozempic-and-sex-drive - Peptides for Sex Drive: PT-141, Kisspeptin and Oxytocin in the Trials: One of these cleared a regulator. Bremelanotide raised desire scores 0.35 points above placebo across 1,267 women. Kisspeptin has two randomized trials in low desire whose endpoint was a brain scan, and intranasal oxytocin did no better than placebo in 30 women. https://thispeptide.org/research/peptides-for-sex-drive - Oxytocin Nasal Spray: What Human Trials of the Intranasal Dose Found: A crossover trial in 30 women with sexual dysfunction found intranasal oxytocin did no better than placebo on any score. https://thispeptide.org/research/oxytocin-nasal-spray - Vyleesi Reviews: What Women in the Trials Reported, and What the Numbers Show: In exit interviews, women who took Vyleesi described more desire and arousal. https://thispeptide.org/research/vyleesi-reviews - How Long Does PT 141 Last? Four Clocks, and the One Nobody Has Timed: PT-141 peaks in the blood within an hour, and a standard half-life estimate puts it largely cleared within about half a day. https://thispeptide.org/research/how-long-does-pt-141-last - Bremelanotide (PT-141): The FDA Approval and What the Trials Showed: Bremelanotide is approved for low sexual desire in premenopausal women. https://thispeptide.org/research/bremelanotide-pt-141-fda-approval-and-trials - Bremelanotide Side Effects: Nausea, Blood Pressure and Skin Darkening: Nausea in 40% of women, a brief blood pressure rise after every dose, and skin darkening that depends heavily on how often it is taken. https://thispeptide.org/research/bremelanotide-side-effects - Kisspeptin: What Human Studies Show About Libido and Reproductive Hormones: Single kisspeptin infusions changed brain responses to sexual cues in men and women with low desire, and raised reproductive hormones. https://thispeptide.org/research/kisspeptin - PT 141 Dosage: The Vyleesi Label's 1.75 mg Dose and What Trials Tested: The label states one dose, 1.75 mg under the skin at least 45 minutes ahead, with limits of one a day and eight a month. https://thispeptide.org/research/pt-141-dosage - PT 141 for Men: What the Erectile Dysfunction Trials Found: Bremelanotide was first tested in men, then approved only for women. https://thispeptide.org/research/pt-141-for-men - PT-141 Nasal Spray: Why Intranasal Bremelanotide Was Dropped in Trials: Bremelanotide was first tested as a nasal spray. https://thispeptide.org/research/pt-141-nasal-spray ### Longevity (29) - Dihexa: The Animal Research and the Retracted Key Paper: Dihexa has never been tested in people. Its rat data come mostly from one lab, an independent 2024 study found no benefit, and the 2014 paper explaining how it works was retracted in 2025. https://thispeptide.org/research/dihexa - Does NAD Cause Cancer? What Human and Animal Studies Show: Cancer cells depend on NAD+, which is why the question comes up. https://thispeptide.org/research/does-nad-cause-cancer - NAC vs Glutathione: Which One Raises Glutathione in People?: NAC hands cells the building block they run short of; glutathione capsules try to deliver the finished molecule. https://thispeptide.org/research/nac-vs-glutathione - NAD for Parkinson's: What the Human Trials Have Found So Far: An oral NAD+ precursor raised NAD+ in the blood and brain of people with Parkinson's in two small, month-long trials. https://thispeptide.org/research/nad-for-parkinsons - Glutathione for Chemotherapy Neuropathy: What the Trials Found: Small trials found less nerve damage when glutathione was infused before cisplatin or oxaliplatin. https://thispeptide.org/research/glutathione-chemotherapy-neuropathy - Semax: what has actually been tested in people: Semax has real human studies behind it, which is rare on this shelf. https://thispeptide.org/research/semax - SS-31 Peptide: Forzinity Approval and Human Evidence: SS-31 is elamipretide, approved as Forzinity for Barth syndrome. https://thispeptide.org/research/ss-31 - Epitalon Benefits: Each Claim and the Study Behind It: The telomere result is real and sits in a dish. https://thispeptide.org/research/epitalon-benefits - Longevity Peptides: What the Human Evidence Shows for Each One: NAD+ precursors raise NAD+ and change little else; oral glutathione raised body stores 30 to 35% over six months; a GHRH analog raised IGF-1 117% in 152 older adults. https://thispeptide.org/research/longevity-peptides - NAD+ and Glutathione: The Biochemical Link, and Whether the Pair Has Been Tested: Cells use NAD+ to make NADPH, the fuel that recycles glutathione, so the pairing has a real pathway behind it. https://thispeptide.org/research/nad-and-glutathione - Peptides for Anti-Aging: What Human Studies Show for Skin, Growth Hormone and NAD+: Oral collagen peptides have the most trials, for skin hydration and elasticity. https://thispeptide.org/research/peptides-for-anti-aging - NAD+ Benefits for Skin: What Studies of NAD+ and Vitamin B3 Show: Skin loses NAD+ with age, and vitamin B3 forms that the body turns into NAD+ have real skin results, including fewer skin cancers in high-risk adults. https://thispeptide.org/research/nad-benefits-for-skin - Peptides for Energy: What Human Studies Actually Measured: The studies behind peptides sold for energy measured fatigue, strength or function, not energy. https://thispeptide.org/research/peptides-for-energy - Glutathione for Liver Health: What the Fatty-Liver Studies Show: The liver relies on glutathione to neutralize toxic drug byproducts, but the studies of taking glutathione for liver disease are small, uncontrolled pilots. https://thispeptide.org/research/glutathione-for-liver - NAD Dosage: What IV, Injection and Oral Studies Actually Used: NAD+ has no label dose. Human studies have given it by vein at 10 to 750 mg, but none in PubMed has tested a shot under the skin. Its oral precursors raised blood levels within weeks. https://thispeptide.org/research/nad-dosage - Glutathione Dosage: What Oral, IV and Nasal Trials Actually Gave: Compounded glutathione comes with no approved dosing label. https://thispeptide.org/research/glutathione-dosage - NMN vs NAD: How the Precursor and the Molecule Itself Compare in Human Studies: NMN is a building block the body turns into NAD+. https://thispeptide.org/research/nmn-vs-nad - Epitalon: What the Telomere Claims Rest On: The telomere results come from cells in a dish, and the human survival studies used a different substance. https://thispeptide.org/research/epitalon - Glutathione for Skin: What Trials of Oral, Topical and Injected Forms Found: Pills and lotions lowered skin melanin readings modestly in small trials. https://thispeptide.org/research/glutathione-for-skin - Glutathione Injections: What the Evidence Shows: One placebo-controlled trial for skin lightening, which missed significance. https://thispeptide.org/research/glutathione-injections-evidence - Glutathione Side Effects: What Injection, IV and Oral Studies Reported: Oral glutathione was well tolerated in trials. https://thispeptide.org/research/glutathione-side-effects - Liposomal Glutathione: Does Oral Glutathione Raise Levels in the Body?: A single oral dose barely registered in 1992. https://thispeptide.org/research/liposomal-glutathione - MOTS-c Dosage: What Mouse and Human Studies Used, and Why No Dose Is Set: Every published MOTS-c dose was given to rodents. https://thispeptide.org/research/mots-c-dosage - MOTS-c: What the Research Shows in Mice and in People: Strong mouse data on insulin resistance and running capacity. https://thispeptide.org/research/mots-c-evidence - NAD+ Injections: The Benefits Claimed, and What Studies in People Measured: Two small IV studies measured blood chemistry or infusion tolerability. https://thispeptide.org/research/nad-injections-benefits - NAD IV Therapy: What Studies of Intravenous NAD+ in People Measured: Drip clinics sell NAD+ for energy and aging. https://thispeptide.org/research/nad-iv-therapy - NAD Nasal Spray: What the Evidence Shows So Far: Animal studies and human data from other routes leave key questions about NAD+ nasal spray unanswered: absorption, safety and benefit in people. https://thispeptide.org/research/nad-nasal-spray - NAD Patches: Can NAD+ Get Through the Skin?: NAD+ is larger than the size skin normally lets through, and no published study has measured NAD+ in human blood after a patch. https://thispeptide.org/research/nad-patches - NAD Side Effects: What Injection, IV and Oral Precursor Studies Reported: IV drips caused stomach symptoms and chest pressure during the infusion. https://thispeptide.org/research/nad-side-effects ### Recovery (21) - GHK-Cu Copper Toxicity: Copper per Milligram vs the Upper Limit: GHK-Cu is 7% to 16% copper by weight, depending on the form. https://thispeptide.org/research/ghk-cu-copper-toxicity - LL-37 peptide: real trials, for something else: LL-37 has randomized controlled trials behind it, which is rare here. https://thispeptide.org/research/ll-37 - KPV peptide: what the research actually shows: KPV is the three-amino-acid tail of alpha-MSH. https://thispeptide.org/research/kpv-peptide - BPC 157 Before and After: What the Human Reports Measured: The published human record is three uncontrolled reports by the same lead author. https://thispeptide.org/research/bpc-157-before-and-after - TB 500 Dosage: What Human Studies of Thymosin Beta-4 Used: No published human study has given TB-500 itself. https://thispeptide.org/research/tb-500-dosage - MK-677 Side Effects: What the Ibutamoren Trials Recorded: A trial in 123 hip-fracture patients was stopped early for a congestive heart failure signal, and FDA cites it by name. https://thispeptide.org/research/mk-677-side-effects - Thymosin Alpha 1: What the Human Trials Actually Measured: A peptide with three decades of trials behind it. https://thispeptide.org/research/thymosin-alpha-1 - GHK-Cu Benefits: Which Claims Have Been Tested in People: The copper peptide is credited with firmer skin, faster healing, thicker hair and less inflammation. https://thispeptide.org/research/ghk-cu-benefits - Peptides for Inflammation: Which Ones Have Human Evidence: Of the four peptides here, only semaglutide has a large randomized trial showing an inflammation marker fall. https://thispeptide.org/research/peptides-for-inflammation - GHK-Cu Dosage: What Studies Applied, and Why No Injected Dose Exists: No label sets a GHK-Cu dose. The only strength tested against placebo, a 0.4% cream on leg ulcers, did no better than placebo, and no study has tested it by injection in people. https://thispeptide.org/research/ghk-cu-dosage - BPC 157 and TB 500 Together: What Any Study Has Tested of the Pair: One rat study tested the pair against each alone, and the combination added nothing. https://thispeptide.org/research/bpc-157-and-tb-500 - BPC 157 Dosage: Why No Human Dose Exists, and What Studies Used: No trial has set a human dose of BPC-157. https://thispeptide.org/research/bpc-157-dosage - BPC-157: What Human Evidence Actually Exists: Thirty-five animal and cell studies, and three small human reports with no control group. https://thispeptide.org/research/bpc-157-human-evidence - BPC-157 Side Effects: What Has Been Recorded in People: Three tiny uncontrolled reports found no adverse events. https://thispeptide.org/research/bpc-157-side-effects - GHK-Cu Side Effects: What Topical Studies Report, and the Injected Unknowns: Only two small trials have tested GHK-Cu alone on skin, and copper is a weak allergen. https://thispeptide.org/research/ghk-cu-side-effects - GHK-Cu: Copper Peptide Evidence, Topical Versus Injected: Two small skin trials, no injection trials, and an FDA list that allows the peptide by every route except the needle. https://thispeptide.org/research/ghk-cu-topical-vs-injected - Peptides for Hair Growth: What the Trials Show: The peptides sold for hair have small trials, all of blends. https://thispeptide.org/research/peptides-for-hair-growth - Peptides for Joint Pain: What Human Trials Exist, Compound by Compound: Oral collagen peptides have randomized trials, with modest benefits and a high risk of bias. https://thispeptide.org/research/peptides-for-joint-pain - Peptides for Muscle Growth: What Trials of GH Secretagogues Measured: Drugs that raise growth hormone added about a kilogram of lean mass in randomized trials. https://thispeptide.org/research/peptides-for-muscle-growth - Peptides for Skin: Which Ones Have Human Trials: Cream peptides, copper peptide and swallowed collagen are three different things. https://thispeptide.org/research/peptides-for-skin - TB-500: What Is Known, and What Has Never Been Tested: A seven-amino-acid fragment with no human data, borrowing its reputation from small trials of the full protein. https://thispeptide.org/research/tb-500-evidence ### Sleep (18) - Selank: what the human trials actually found: Selank is one of the few research peptides tested in people. https://thispeptide.org/research/selank - DSIP Dosage: The Doses Used in the Human Studies: Four human studies used the same figure: 25 nanomoles per kilogram, into a vein. https://thispeptide.org/research/dsip-dosage - Semaglutide Insomnia: What the Labels and Sleep Studies Record: Insomnia does not appear in the Wegovy or Ozempic label, and no randomized trial has measured it. https://thispeptide.org/research/semaglutide-insomnia - Zepbound for Sleep Apnea: What the SURMOUNT-OSA Trials Found: Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. https://thispeptide.org/research/zepbound-sleep-apnea - Sermorelin vs HGH: A Signal to the Pituitary or the Hormone Itself: Sermorelin asks the pituitary to release growth hormone; HGH is the hormone. https://thispeptide.org/research/sermorelin-vs-hgh - CJC 1295 and Ipamorelin: What Human Studies Exist for the Pair: Each peptide has a thin human record of its own. https://thispeptide.org/research/cjc-1295-ipamorelin - Does Sermorelin Work? What the Human Studies Measured: Small studies in older men show sermorelin raises growth hormone, and at twice-daily doses IGF-1. https://thispeptide.org/research/does-sermorelin-work - DSIP Peptide: What Delta Sleep-Inducing Peptide Trials in People Found: One small double-blind study found better sleep; two others found effects too weak to matter. https://thispeptide.org/research/dsip-peptide - Growth Hormone Peptides: GHRH Analogs vs Ghrelin Mimetics, and Their Evidence: Every growth hormone peptide works through one of two receptors. https://thispeptide.org/research/growth-hormone-peptides - Ipamorelin: What the Human Evidence Actually Shows: One dosing study in healthy men and one bowel-surgery trial that missed its goal. https://thispeptide.org/research/ipamorelin - Ipamorelin Side Effects: What the Few Human Trials Recorded: Two small human studies, both by vein, make up the record. https://thispeptide.org/research/ipamorelin-side-effects - Peptides for Sleep: What Human Studies of GHRH and DSIP Found: GHRH deepened sleep in young men, worsened it in young women and did less in older adults. https://thispeptide.org/research/peptides-for-sleep - Sermorelin Before and After: What Trials Measured Over Weeks and Months: The sermorelin studies published no photos. https://thispeptide.org/research/sermorelin-before-and-after - Sermorelin Dosage: What the Approved Product and Trials Actually Used: A single diagnostic dose, a nightly pediatric regimen, and two small studies in older men. https://thispeptide.org/research/sermorelin-dosage - Sermorelin Nasal Spray: Does GHRH Work Without an Injection?: The only approved sermorelin was an injection. https://thispeptide.org/research/sermorelin-nasal-spray - Sermorelin Side Effects: What the Trials and FDA Record Report: Flushing and injection-site pain are the reported side effects. https://thispeptide.org/research/sermorelin-side-effects - Sermorelin vs Ipamorelin: Two Very Different Evidence Records: No head-to-head trial turns up in PubMed. https://thispeptide.org/research/sermorelin-vs-ipamorelin - Tesamorelin vs Sermorelin: Two GHRH Analogs With Very Different Evidence: Both copy the hormone that tells the pituitary to release growth hormone. https://thispeptide.org/research/tesamorelin-vs-sermorelin ### Every goal (18) - Compounded Semaglutide Dosing Errors: Where Confusion Starts: Concentration, milligrams, milliliters and syringe markings can be confused. https://thispeptide.org/research/compounded-semaglutide-dosing-errors - How to Report Peptide Side Effects: MedWatch and the Details to Save: Get care first, then preserve the label, lot number and timeline. https://thispeptide.org/research/how-to-report-peptide-side-effects - Peptide Blends Safety: Does Combining Ingredients Improve the Evidence?: A blend needs evidence for its ingredients, combination and route. https://thispeptide.org/research/peptide-blends-safety - Peptide Clinical Trials: How to Check What a Study Actually Tests: A trial listing can help you find legitimate research. https://thispeptide.org/research/peptide-clinical-trials - Peptide Vial Beyond Use Date: The Label and the First-Puncture Clock: A beyond-use date and an opened-vial limit are different. https://thispeptide.org/research/peptide-vial-beyond-use-date - Semaglutide Sodium vs Base: Why the Ingredient Matters: FDA distinguishes semaglutide base from sodium and acetate salts. https://thispeptide.org/research/semaglutide-sodium-vs-base - What Does FDA Approved Mean for a Peptide Medicine?: Approval attaches to a particular product and its labeling. https://thispeptide.org/research/what-does-fda-approved-mean - Corporate Practice of Medicine in Telehealth: Who Is Your Doctor?: Telehealth peptide and GLP-1 sites say they do not practice medicine. https://thispeptide.org/research/corporate-practice-of-medicine-telehealth - LegitScript Certified Meaning: A License Check, Not a Lab Test: Telehealth and peptide sellers display a LegitScript seal. https://thispeptide.org/research/legitscript-certified-meaning - How to Read a Peptide COA, and What It Cannot Prove: Sellers promise third-party certificates of analysis but rarely show one. https://thispeptide.org/research/how-to-read-a-peptide-coa - Your Peptides Arrived Warm: What the Stability Studies Measured: FDA advises against using injectable GLP-1 medicine that arrives warm. https://thispeptide.org/research/peptides-arrived-warm - Are Peptides Legal? FDA Categories, 503A, 503B and "Research Use Only": It depends on the peptide and the route: approved drug, pharmacy compounding, or neither. https://thispeptide.org/research/are-peptides-legal - Are Peptides Safe? It Depends on Which One, and Where It Came From: Approved peptides have known, labeled side effects. https://thispeptide.org/research/are-peptides-safe - Bacteriostatic Water for Peptides: What the Labels Say: Sterile water with a preservative, for use only as the drug's own label directs. https://thispeptide.org/research/bacteriostatic-water-for-peptides - How to Reconstitute Peptides: What the Drug Labels Instruct: FDA-approved labels agree on the diluent, gentle mixing and a clear solution. https://thispeptide.org/research/how-to-reconstitute-peptides - How to Store Peptides: What Four Drug Labels Require: Fridge for some, room temperature for others, never the freezer. https://thispeptide.org/research/how-to-store-peptides - Peptide Injection Sites: Where the Labels Say to Inject: Abdomen, thigh, sometimes the upper arm: each FDA-approved label names its own sites, and every one says to rotate. https://thispeptide.org/research/peptide-injection-sites - What Are Peptides? How They Work, and Why Most Are Injected: Peptides are short chains of amino acids that act as signals. https://thispeptide.org/research/what-are-peptides ## How a seller gets listed - A seller is named only once this site has written a review of it from its own public pages. 460 of the 601 sellers tracked are reviewed. - Prices are the seller's own published starting figures, in the unit the seller states (per month, per vial). A vial is never converted into a month. Where a required fee or a package length changes what a month costs, our monthly total follows the seller's figure and is labeled as ours. - A research-only peptide never gets a seller link, a price or a dose, even when a seller sells it. - Some seller links earn this site a commission, and each is labeled Partner wherever it appears. A commission never changes what a review says. - Methodology: https://thispeptide.org/methodology - Affiliate disclosure: https://thispeptide.org/disclosures ## Citing this site - Short form: This Peptide (thispeptide.org), "", , . - With the method: According to This Peptide, which reads each peptide's status from a dated FDA source and labels the evidence by the size and design of the studies it cites (), ... - Keep the qualifier with the claim: a status without its FDA source, or an evidence label without the studies it rests on, misstates the page. - Who writes and checks it: https://thispeptide.org/authors (Leah Garner, clinical-evidence editor; Molly Ward, goal-guide writer; Craig Palmer, peptide pharmacology writer; Paul Hardy, standards editor) - Editorial policy: https://thispeptide.org/editorial-policy - Corrections: https://thispeptide.org/corrections ## About the desk - About this site: https://thispeptide.org/about - Methodology: https://thispeptide.org/methodology - How reviews are written: https://thispeptide.org/nature-of-reviews - Medical disclaimer: https://thispeptide.org/medical-disclaimer - Contact: https://thispeptide.org/contact ## Terms for AI systems Quote and cite this material with attribution to This Peptide (https://thispeptide.org). Please preserve the qualifier attached to any evidence claim: the qualifier is the claim. Not medical advice. Last generated: November 2026 ## Complete canonical page discovery Every indexable canonical page, including new page families, is included in this automatically generated inventory. Follow all linked parts; no page limit is applied. - Complete page index, text and sources: https://thispeptide.org/llms-pages/index.txt - Complete updates feed: https://thispeptide.org/feed.xml - Sitemap: https://thispeptide.org/sitemap.xml